Predict your next investment

National Comprehensive Cancer Network company logo
HEALTHCARE | Medical Facilities & Services
nccn.org

See what CB Insights has to offer

Founded Year

1995

Stage

Grant - VII | Alive

Total Raised

$16.2M

Last Raised

$2M | 3 yrs ago

About National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. NCCN develops resources that present information to the numerous stakeholders in the healthcare delivery system.

National Comprehensive Cancer Network Headquarter Location

3025 Chemical Road Suite 100

Plymouth Meeting, Pennsylvania, 19462,

United States

215-690-0300

Latest National Comprehensive Cancer Network News

New research finds disturbing lack of crucial blood cancer medication

Nov 17, 2021

New research in the November 2021 issue of JNCCN-;Journal of the National Comprehensive Cancer Network finds fewer than one-third of hospitals had immediate availability of a crucial blood cancer medication called all-trans retinoic acid (ATRA). ATRA is initiated early in the treatment of acute promyelocytic leukemia (APL)-;a form of acute myeloid leukemia (AML), to prevent major bleeding, clotting, and potential death. APL is very treatable and tends to have a better prognosis than other subtypes of AML when treated appropriately. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for AML, along with other international evidence-based guidelines, recommend the immediate initiation of ATRA for patients even suspected of having APL while waiting for genetic confirmation of the diagnosis-;due to the likelihood of early disseminated intravascular coagulopathy (DIC), a life-threatening bleeding disorder. However, when researchers conducted a telephone survey of 120 randomly selected hospitals from different regions around the United States, they found that only approximately 31% of hospitals-;and just 14% of hospitals that refer patients with leukemia elsewhere-;had ATRA immediately available. Furthermore, 42% of the hospitals that confirmed they do treat patients with acute leukemia did not have ATRA in stock. "The loss of a patient with a highly curable leukemia due to the lack of access to a pill for formulary reasons would be devastating," said Dale Bixby, MD, PhD, Michigan Medicine and University of Michigan Medical School. "We hope our study will lead to more widespread knowledge of the lack of availability of ATRA in hospital systems within the U.S. and spur a call to action from pharmacists and hematologists to ensure it is readily available at their institution." According to the survey results, the main reasons for lack of availability of ATRA were related to the rarity of APL and included: the drug had not recently been requested; the inpatient pharmacist was not familiar with the drug; or the facility relied on associated hospitals or cancer centers to provide the drug. The lack of immediate availability of ATRA at 42% of centers who treat acute leukemia was shocking and sobering." James K. Mangan, MD, PhD, Associate Clinical Professor of Medicine, Division of Blood and Marrow Transplantation, UC San Diego, Moores Cancer Center Related Stories Dr. Mangan, a Member of the NCCN Guidelines® Panel for AML continued: "Furthermore, given that transfers from referring centers often take days due to bed availability issues, the lack of availability of ATRA at 86% of referring centers is a truly dangerous situation. This illustrates another reason why SEER database analysis shows that real-world outcomes for Acute Promyelocytic Leukemia lag far behind the excellent outcomes reported in clinical trials. It is a clarion call to action to lobby for inclusion of ATRA on the formularies of all hospitals who encounter acute leukemia patients, no matter whether they are a referring or treating center." Previous research cited in the study found that 11% of patients with APL died within 30 days of presentation for medical care. When ATRA was administered within one day of a suspected diagnosis of APL 33% of the early deaths were from bleeding, while for those who received ATRA after more than one day from suspected diagnosis, 70% of the early deaths were from bleeding. Source:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing National Comprehensive Cancer Network

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

National Comprehensive Cancer Network is included in 1 Expert Collection, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

National Comprehensive Cancer Network Patents

National Comprehensive Cancer Network has filed 11 patents.

The 3 most popular patent topics include:

  • Graphical control elements
  • Graphical user interface elements
  • Graphical user interfaces
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/26/2019

8/3/2021

Graphical user interface elements, Inflammations, Graphical user interfaces, Medical terminology, Graphical control elements

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/26/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/3/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Graphical user interface elements, Inflammations, Graphical user interfaces, Medical terminology, Graphical control elements

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

National Comprehensive Cancer Network Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

National Comprehensive Cancer Network Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.